Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Mar 19, 2024
2024 Sanofi Biogenius Canada Grants open for applications
Photos
1
Feb 20, 2024
JDRF Canada and Sanofi Canada partner to raise awareness about autoimmune type 1 diabetes and the critical role of screening in its early detection
Photos
1
Jan 30, 2024
Sanofi Canada is celebrating 110 years of innovative health solutions for Canadians
Jul 25, 2023
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023
Dupixent® (dupilumab injection) receives marketing authorization for prurigo nodularis
Jul 6, 2023
Sanofi Canada awards third annual Sanofi Biogenius Canada Grants to enhance STEM learning for students
Jun 13, 2023
Sanofi Canada Celebrates Winners of the 2023 Sanofi Biogenius Canada Competition
Jun 12, 2023
Icy Hot® Partners with KidSport Canada to Help Kids Get in the Game
May 4, 2023
DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
May 1, 2023
Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
10
11
»
